FAK Managing Partner Pushes for Increased Investment in R&D

Managing Partner of Fisher Adams Kelly and President of LESANZ, Mark Horsburgh tellsBiotechnologyNews.Net that there is no doubt more investment in genuine R&D activity would create a more competitive environment for biomedical and pharmaceutical innovation. Read the full article here:

http://www.biotechnologynews.net/StoryView.asp?StoryID=2393960